ANXA3 and ovarian carcinoma: Likewise, a substantially increased ANXA3 expression has been found in the serum of platinum-resistant ovarian cancer patients compared to the platinum sensitive group, which underscored the value of ANXA3 as a noninvasive marker for drug response prediction (Yin et al., 2012).